Table 4.
Cancer Type | CXC Chemokine | Effects | References |
---|---|---|---|
Lung cancer | CXCL1/2/5/6/7 CXCL4/8/9/10//11(early-stage) |
Tumor promotion | [81,116,117,138] |
Gastric cancer (GC) | CXCL1/13 CXCL5/8 (late-stage) |
Tumor promotion. CXCL13 could be used to stratify GC patients in the T2–4 stage, and low expression of it predicts better therapy response |
[110,120,134,135] |
Colorectal cancer (CRC) | CXCL1/2/3/5/8/11 (up) CXCL12/14 (down) |
Tumor promotion | [133] |
Esophageal adenocarcinoma | CXCL8 (late-stage) | Tumor promotion | [136] |
Oral squamous carcinoma | CXCL1 | Tumor promotion | [13] |
Pancreatic carcinoma | CXCL3/8/12 | Tumor promotion | [9,85,121] |
Hepatocellular carcinoma | CXCL1/3/5 CXCL13 (late-stage) |
Tumor promotion | [10,137] |
Triple-negative breast cancer (TNBC) | CXCL1/2/8 | Tumor promotion | [37] |
Cervical cancer | CXCL1/2 | Tumor promotion | [119] |
Ovarian cancer | CXCL1/9 | Tumor promotion | [118] |
Prostate cancer | CXCL8/13 | Tumor promotion | [32,44] |
Bladder cancer | CXCL1/5/8/12 | Tumor promotion | [113,114,139,140] |
Clear cell renal cell carcinoma | CXCL7 (down) | Tumor promotion | [138] |
Melanoma | CXCL1/8 | Tumor promotion | [20,141] |
Head and neck squamous cell carcinoma (HNSCC) | CXCL5/8 | Tumor promotion | [142,143] |
Thyroid cancer | CXCL8/12 CXCL10 (down) |
Tumor promotion | [115,144,145] |
Liposarcoma, Osteosarcoma | CXCL4 (early-stage) | Tumor promotion | [112] |
B-cell acute lymphoblastic leukemia | CXCL13 | Tumor promotion | [57] |